Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes Article Swipe
Ali Muhammed Ali
,
Robert Martinez
,
Hussein Al-Jobori
,
John M. Adams
,
Curtis Triplitt
,
Ralph A. DeFronzo
,
Eugênio Cersósimo
,
Muhammad Abdul-Ghani
·
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.2337/dc18-2460
YOU?
·
· 2020
· Open Access
·
· DOI: https://doi.org/10.2337/dc18-2460
OBJECTIVE To examine the effect of combination therapy with canagliflozin plus liraglutide on HbA1c, endogenous glucose production (EGP), and body weight versus each therapy alone. RESEARCH DESIGN AND METHODS Forty-five patients with poorly controlled (HbA1c 7–11%) type 2 diabetes mellitus (T2DM) on metformin with or without sulfonylurea received a 9-h measurement of EGP with [3-3H]glucose infusion, after which they were randomized to receive 1) liraglutide 1.2 mg/day (LIRA), 2) canagliflozin 100 mg/day (CANA), or 3) liraglutide 1.2 mg plus canagliflozin 100 mg (CANA/LIRA) for 16 weeks. At 16 weeks, the EGP measurement was repeated. RESULTS The mean decrease from baseline to 16 weeks in HbA1c was −1.67 ± 0.29% (P = 0.0001), −0.89 ± 0.24% (P = 0.002), and −1.44 ± 0.39% (P = 0.004) in patients receiving CANA/LIRA, CANA, and LIRA, respectively. The decrease in body weight was −6.0 ± 0.8 kg (P < 0.0001), −3.5 ± 0.5 kg (P < 0.0001), and −1.9 ± 0.8 kg (P = 0.03), respectively. CANA monotherapy caused a 9% increase in basal rate of EGP (P < 0.05), which was accompanied by a 50% increase (P < 0.05) in plasma glucagon-to-insulin ratio. LIRA monotherapy reduced plasma glucagon concentration and inhibited EGP. In CANA/LIRA-treated patients, EGP increased by 15% (P < 0.05), even though the plasma insulin response was maintained at baseline and the CANA-induced rise in plasma glucagon concentration was blocked. CONCLUSIONS These results demonstrate that liraglutide failed to block the increase in EGP caused by canagliflozin despite blocking the rise in plasma glucagon and preventing the decrease in plasma insulin concentration caused by canagliflozin. The failure of liraglutide to prevent the increase in EGP caused by canagliflozin explains the lack of additive effect of these two agents on HbA1c.
Related Topics
Concepts
Canagliflozin
Liraglutide
Medicine
Type 2 diabetes
Diabetes mellitus
Weight loss
Internal medicine
Combination therapy
Endocrinology
Obesity
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.2337/dc18-2460
- https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdf
- OA Status
- bronze
- Cited By
- 43
- References
- 21
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W3013979982
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W3013979982Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.2337/dc18-2460Digital Object Identifier
- Title
-
Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 DiabetesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2020Year of publication
- Publication date
-
2020-03-27Full publication date if available
- Authors
-
Ali Muhammed Ali, Robert Martinez, Hussein Al-Jobori, John M. Adams, Curtis Triplitt, Ralph A. DeFronzo, Eugênio Cersósimo, Muhammad Abdul-GhaniList of authors in order
- Landing page
-
https://doi.org/10.2337/dc18-2460Publisher landing page
- PDF URL
-
https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
bronzeOpen access status per OpenAlex
- OA URL
-
https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdfDirect OA link when available
- Concepts
-
Canagliflozin, Liraglutide, Medicine, Type 2 diabetes, Diabetes mellitus, Weight loss, Internal medicine, Combination therapy, Endocrinology, ObesityTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
43Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 6, 2024: 5, 2023: 12, 2022: 5, 2021: 6Per-year citation counts (last 5 years)
- References (count)
-
21Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W3013979982 |
|---|---|
| doi | https://doi.org/10.2337/dc18-2460 |
| ids.doi | https://doi.org/10.2337/dc18-2460 |
| ids.mag | 3013979982 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/32220916 |
| ids.openalex | https://openalex.org/W3013979982 |
| fwci | 5.59032667 |
| mesh[0].qualifier_ui | Q000187 |
| mesh[0].descriptor_ui | D001786 |
| mesh[0].is_major_topic | False |
| mesh[0].qualifier_name | drug effects |
| mesh[0].descriptor_name | Blood Glucose |
| mesh[1].qualifier_ui | Q000378 |
| mesh[1].descriptor_ui | D001786 |
| mesh[1].is_major_topic | False |
| mesh[1].qualifier_name | metabolism |
| mesh[1].descriptor_name | Blood Glucose |
| mesh[2].qualifier_ui | Q000008 |
| mesh[2].descriptor_ui | D000068896 |
| mesh[2].is_major_topic | False |
| mesh[2].qualifier_name | administration & dosage |
| mesh[2].descriptor_name | Canagliflozin |
| mesh[3].qualifier_ui | Q000009 |
| mesh[3].descriptor_ui | D000068896 |
| mesh[3].is_major_topic | False |
| mesh[3].qualifier_name | adverse effects |
| mesh[3].descriptor_name | Canagliflozin |
| mesh[4].qualifier_ui | Q000097 |
| mesh[4].descriptor_ui | D003924 |
| mesh[4].is_major_topic | False |
| mesh[4].qualifier_name | blood |
| mesh[4].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[5].qualifier_ui | Q000188 |
| mesh[5].descriptor_ui | D003924 |
| mesh[5].is_major_topic | False |
| mesh[5].qualifier_name | drug therapy |
| mesh[5].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[6].qualifier_ui | Q000652 |
| mesh[6].descriptor_ui | D003924 |
| mesh[6].is_major_topic | False |
| mesh[6].qualifier_name | urine |
| mesh[6].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[7].qualifier_ui | |
| mesh[7].descriptor_ui | D004357 |
| mesh[7].is_major_topic | False |
| mesh[7].qualifier_name | |
| mesh[7].descriptor_name | Drug Synergism |
| mesh[8].qualifier_ui | |
| mesh[8].descriptor_ui | D004359 |
| mesh[8].is_major_topic | False |
| mesh[8].qualifier_name | |
| mesh[8].descriptor_name | Drug Therapy, Combination |
| mesh[9].qualifier_ui | |
| mesh[9].descriptor_ui | D005260 |
| mesh[9].is_major_topic | False |
| mesh[9].qualifier_name | |
| mesh[9].descriptor_name | Female |
| mesh[10].qualifier_ui | Q000187 |
| mesh[10].descriptor_ui | D006442 |
| mesh[10].is_major_topic | False |
| mesh[10].qualifier_name | drug effects |
| mesh[10].descriptor_name | Glycated Hemoglobin |
| mesh[11].qualifier_ui | Q000378 |
| mesh[11].descriptor_ui | D006442 |
| mesh[11].is_major_topic | False |
| mesh[11].qualifier_name | metabolism |
| mesh[11].descriptor_name | Glycated Hemoglobin |
| mesh[12].qualifier_ui | |
| mesh[12].descriptor_ui | D000085002 |
| mesh[12].is_major_topic | False |
| mesh[12].qualifier_name | |
| mesh[12].descriptor_name | Glycemic Control |
| mesh[13].qualifier_ui | Q000139 |
| mesh[13].descriptor_ui | D006029 |
| mesh[13].is_major_topic | False |
| mesh[13].qualifier_name | chemically induced |
| mesh[13].descriptor_name | Glycosuria |
| mesh[14].qualifier_ui | Q000652 |
| mesh[14].descriptor_ui | D006029 |
| mesh[14].is_major_topic | False |
| mesh[14].qualifier_name | urine |
| mesh[14].descriptor_name | Glycosuria |
| mesh[15].qualifier_ui | |
| mesh[15].descriptor_ui | D006801 |
| mesh[15].is_major_topic | False |
| mesh[15].qualifier_name | |
| mesh[15].descriptor_name | Humans |
| mesh[16].qualifier_ui | Q000008 |
| mesh[16].descriptor_ui | D007004 |
| mesh[16].is_major_topic | False |
| mesh[16].qualifier_name | administration & dosage |
| mesh[16].descriptor_name | Hypoglycemic Agents |
| mesh[17].qualifier_ui | Q000009 |
| mesh[17].descriptor_ui | D007004 |
| mesh[17].is_major_topic | False |
| mesh[17].qualifier_name | adverse effects |
| mesh[17].descriptor_name | Hypoglycemic Agents |
| mesh[18].qualifier_ui | Q000008 |
| mesh[18].descriptor_ui | D000069450 |
| mesh[18].is_major_topic | False |
| mesh[18].qualifier_name | administration & dosage |
| mesh[18].descriptor_name | Liraglutide |
| mesh[19].qualifier_ui | Q000009 |
| mesh[19].descriptor_ui | D000069450 |
| mesh[19].is_major_topic | False |
| mesh[19].qualifier_name | adverse effects |
| mesh[19].descriptor_name | Liraglutide |
| mesh[20].qualifier_ui | |
| mesh[20].descriptor_ui | D008297 |
| mesh[20].is_major_topic | False |
| mesh[20].qualifier_name | |
| mesh[20].descriptor_name | Male |
| mesh[21].qualifier_ui | |
| mesh[21].descriptor_ui | D008875 |
| mesh[21].is_major_topic | False |
| mesh[21].qualifier_name | |
| mesh[21].descriptor_name | Middle Aged |
| mesh[22].qualifier_ui | |
| mesh[22].descriptor_ui | D016896 |
| mesh[22].is_major_topic | False |
| mesh[22].qualifier_name | |
| mesh[22].descriptor_name | Treatment Outcome |
| mesh[23].qualifier_ui | Q000187 |
| mesh[23].descriptor_ui | D015431 |
| mesh[23].is_major_topic | False |
| mesh[23].qualifier_name | drug effects |
| mesh[23].descriptor_name | Weight Loss |
| mesh[24].qualifier_ui | Q000187 |
| mesh[24].descriptor_ui | D001786 |
| mesh[24].is_major_topic | False |
| mesh[24].qualifier_name | drug effects |
| mesh[24].descriptor_name | Blood Glucose |
| mesh[25].qualifier_ui | Q000378 |
| mesh[25].descriptor_ui | D001786 |
| mesh[25].is_major_topic | False |
| mesh[25].qualifier_name | metabolism |
| mesh[25].descriptor_name | Blood Glucose |
| mesh[26].qualifier_ui | Q000008 |
| mesh[26].descriptor_ui | D000068896 |
| mesh[26].is_major_topic | False |
| mesh[26].qualifier_name | administration & dosage |
| mesh[26].descriptor_name | Canagliflozin |
| mesh[27].qualifier_ui | Q000009 |
| mesh[27].descriptor_ui | D000068896 |
| mesh[27].is_major_topic | False |
| mesh[27].qualifier_name | adverse effects |
| mesh[27].descriptor_name | Canagliflozin |
| mesh[28].qualifier_ui | Q000097 |
| mesh[28].descriptor_ui | D003924 |
| mesh[28].is_major_topic | False |
| mesh[28].qualifier_name | blood |
| mesh[28].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[29].qualifier_ui | Q000188 |
| mesh[29].descriptor_ui | D003924 |
| mesh[29].is_major_topic | False |
| mesh[29].qualifier_name | drug therapy |
| mesh[29].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[30].qualifier_ui | Q000652 |
| mesh[30].descriptor_ui | D003924 |
| mesh[30].is_major_topic | False |
| mesh[30].qualifier_name | urine |
| mesh[30].descriptor_name | Diabetes Mellitus, Type 2 |
| mesh[31].qualifier_ui | |
| mesh[31].descriptor_ui | D004357 |
| mesh[31].is_major_topic | False |
| mesh[31].qualifier_name | |
| mesh[31].descriptor_name | Drug Synergism |
| mesh[32].qualifier_ui | |
| mesh[32].descriptor_ui | D004359 |
| mesh[32].is_major_topic | False |
| mesh[32].qualifier_name | |
| mesh[32].descriptor_name | Drug Therapy, Combination |
| mesh[33].qualifier_ui | |
| mesh[33].descriptor_ui | D005260 |
| mesh[33].is_major_topic | False |
| mesh[33].qualifier_name | |
| mesh[33].descriptor_name | Female |
| mesh[34].qualifier_ui | Q000187 |
| mesh[34].descriptor_ui | D006442 |
| mesh[34].is_major_topic | False |
| mesh[34].qualifier_name | drug effects |
| mesh[34].descriptor_name | Glycated Hemoglobin |
| mesh[35].qualifier_ui | Q000378 |
| mesh[35].descriptor_ui | D006442 |
| mesh[35].is_major_topic | False |
| mesh[35].qualifier_name | metabolism |
| mesh[35].descriptor_name | Glycated Hemoglobin |
| mesh[36].qualifier_ui | |
| mesh[36].descriptor_ui | D000085002 |
| mesh[36].is_major_topic | False |
| mesh[36].qualifier_name | |
| mesh[36].descriptor_name | Glycemic Control |
| mesh[37].qualifier_ui | Q000139 |
| mesh[37].descriptor_ui | D006029 |
| mesh[37].is_major_topic | False |
| mesh[37].qualifier_name | chemically induced |
| mesh[37].descriptor_name | Glycosuria |
| mesh[38].qualifier_ui | Q000652 |
| mesh[38].descriptor_ui | D006029 |
| mesh[38].is_major_topic | False |
| mesh[38].qualifier_name | urine |
| mesh[38].descriptor_name | Glycosuria |
| mesh[39].qualifier_ui | |
| mesh[39].descriptor_ui | D006801 |
| mesh[39].is_major_topic | False |
| mesh[39].qualifier_name | |
| mesh[39].descriptor_name | Humans |
| mesh[40].qualifier_ui | Q000008 |
| mesh[40].descriptor_ui | D007004 |
| mesh[40].is_major_topic | False |
| mesh[40].qualifier_name | administration & dosage |
| mesh[40].descriptor_name | Hypoglycemic Agents |
| mesh[41].qualifier_ui | Q000009 |
| mesh[41].descriptor_ui | D007004 |
| mesh[41].is_major_topic | False |
| mesh[41].qualifier_name | adverse effects |
| mesh[41].descriptor_name | Hypoglycemic Agents |
| mesh[42].qualifier_ui | Q000008 |
| mesh[42].descriptor_ui | D000069450 |
| mesh[42].is_major_topic | False |
| mesh[42].qualifier_name | administration & dosage |
| mesh[42].descriptor_name | Liraglutide |
| mesh[43].qualifier_ui | Q000009 |
| mesh[43].descriptor_ui | D000069450 |
| mesh[43].is_major_topic | False |
| mesh[43].qualifier_name | adverse effects |
| mesh[43].descriptor_name | Liraglutide |
| mesh[44].qualifier_ui | |
| mesh[44].descriptor_ui | D008297 |
| mesh[44].is_major_topic | False |
| mesh[44].qualifier_name | |
| mesh[44].descriptor_name | Male |
| mesh[45].qualifier_ui | |
| mesh[45].descriptor_ui | D008875 |
| mesh[45].is_major_topic | False |
| mesh[45].qualifier_name | |
| mesh[45].descriptor_name | Middle Aged |
| mesh[46].qualifier_ui | |
| mesh[46].descriptor_ui | D016896 |
| mesh[46].is_major_topic | False |
| mesh[46].qualifier_name | |
| mesh[46].descriptor_name | Treatment Outcome |
| mesh[47].qualifier_ui | Q000187 |
| mesh[47].descriptor_ui | D015431 |
| mesh[47].is_major_topic | False |
| mesh[47].qualifier_name | drug effects |
| mesh[47].descriptor_name | Weight Loss |
| type | article |
| title | Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes |
| biblio.issue | 6 |
| biblio.volume | 43 |
| biblio.last_page | 1241 |
| biblio.first_page | 1234 |
| grants[0].funder | https://openalex.org/F4320337601 |
| grants[0].award_id | |
| grants[0].funder_display_name | Janssen Pharmaceuticals |
| topics[0].id | https://openalex.org/T10401 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 1.0 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2712 |
| topics[0].subfield.display_name | Endocrinology, Diabetes and Metabolism |
| topics[0].display_name | Diabetes Treatment and Management |
| topics[1].id | https://openalex.org/T12539 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9976000189781189 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2736 |
| topics[1].subfield.display_name | Pharmacology |
| topics[1].display_name | Pharmacology and Obesity Treatment |
| topics[2].id | https://openalex.org/T11339 |
| topics[2].field.id | https://openalex.org/fields/13 |
| topics[2].field.display_name | Biochemistry, Genetics and Molecular Biology |
| topics[2].score | 0.9966999888420105 |
| topics[2].domain.id | https://openalex.org/domains/1 |
| topics[2].domain.display_name | Life Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/1312 |
| topics[2].subfield.display_name | Molecular Biology |
| topics[2].display_name | Metabolism, Diabetes, and Cancer |
| funders[0].id | https://openalex.org/F4320337601 |
| funders[0].ror | https://ror.org/03qd7mz70 |
| funders[0].display_name | Janssen Pharmaceuticals |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| concepts[0].id | https://openalex.org/C2777451236 |
| concepts[0].level | 4 |
| concepts[0].score | 0.9698328971862793 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q5030940 |
| concepts[0].display_name | Canagliflozin |
| concepts[1].id | https://openalex.org/C2781308992 |
| concepts[1].level | 4 |
| concepts[1].score | 0.962349534034729 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q2526479 |
| concepts[1].display_name | Liraglutide |
| concepts[2].id | https://openalex.org/C71924100 |
| concepts[2].level | 0 |
| concepts[2].score | 0.9436048269271851 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[2].display_name | Medicine |
| concepts[3].id | https://openalex.org/C2777180221 |
| concepts[3].level | 3 |
| concepts[3].score | 0.777294397354126 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q3025883 |
| concepts[3].display_name | Type 2 diabetes |
| concepts[4].id | https://openalex.org/C555293320 |
| concepts[4].level | 2 |
| concepts[4].score | 0.717540979385376 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q12206 |
| concepts[4].display_name | Diabetes mellitus |
| concepts[5].id | https://openalex.org/C544821477 |
| concepts[5].level | 3 |
| concepts[5].score | 0.5752217173576355 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q718113 |
| concepts[5].display_name | Weight loss |
| concepts[6].id | https://openalex.org/C126322002 |
| concepts[6].level | 1 |
| concepts[6].score | 0.4773464500904083 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[6].display_name | Internal medicine |
| concepts[7].id | https://openalex.org/C2776999253 |
| concepts[7].level | 2 |
| concepts[7].score | 0.42694681882858276 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q1304270 |
| concepts[7].display_name | Combination therapy |
| concepts[8].id | https://openalex.org/C134018914 |
| concepts[8].level | 1 |
| concepts[8].score | 0.36744141578674316 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q162606 |
| concepts[8].display_name | Endocrinology |
| concepts[9].id | https://openalex.org/C511355011 |
| concepts[9].level | 2 |
| concepts[9].score | 0.19915828108787537 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q12174 |
| concepts[9].display_name | Obesity |
| keywords[0].id | https://openalex.org/keywords/canagliflozin |
| keywords[0].score | 0.9698328971862793 |
| keywords[0].display_name | Canagliflozin |
| keywords[1].id | https://openalex.org/keywords/liraglutide |
| keywords[1].score | 0.962349534034729 |
| keywords[1].display_name | Liraglutide |
| keywords[2].id | https://openalex.org/keywords/medicine |
| keywords[2].score | 0.9436048269271851 |
| keywords[2].display_name | Medicine |
| keywords[3].id | https://openalex.org/keywords/type-2-diabetes |
| keywords[3].score | 0.777294397354126 |
| keywords[3].display_name | Type 2 diabetes |
| keywords[4].id | https://openalex.org/keywords/diabetes-mellitus |
| keywords[4].score | 0.717540979385376 |
| keywords[4].display_name | Diabetes mellitus |
| keywords[5].id | https://openalex.org/keywords/weight-loss |
| keywords[5].score | 0.5752217173576355 |
| keywords[5].display_name | Weight loss |
| keywords[6].id | https://openalex.org/keywords/internal-medicine |
| keywords[6].score | 0.4773464500904083 |
| keywords[6].display_name | Internal medicine |
| keywords[7].id | https://openalex.org/keywords/combination-therapy |
| keywords[7].score | 0.42694681882858276 |
| keywords[7].display_name | Combination therapy |
| keywords[8].id | https://openalex.org/keywords/endocrinology |
| keywords[8].score | 0.36744141578674316 |
| keywords[8].display_name | Endocrinology |
| keywords[9].id | https://openalex.org/keywords/obesity |
| keywords[9].score | 0.19915828108787537 |
| keywords[9].display_name | Obesity |
| language | en |
| locations[0].id | doi:10.2337/dc18-2460 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S49878492 |
| locations[0].source.issn | 0149-5992, 1935-5548 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | False |
| locations[0].source.issn_l | 0149-5992 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Diabetes Care |
| locations[0].source.host_organization | https://openalex.org/P4310320274 |
| locations[0].source.host_organization_name | American Diabetes Association |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320274 |
| locations[0].source.host_organization_lineage_names | American Diabetes Association |
| locations[0].license | |
| locations[0].pdf_url | https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Diabetes Care |
| locations[0].landing_page_url | https://doi.org/10.2337/dc18-2460 |
| locations[1].id | pmid:32220916 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Diabetes care |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/32220916 |
| locations[2].id | pmh:oai:pubmedcentral.nih.gov:7411279 |
| locations[2].is_oa | True |
| locations[2].source.id | https://openalex.org/S2764455111 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | PubMed Central |
| locations[2].source.host_organization | https://openalex.org/I1299303238 |
| locations[2].source.host_organization_name | National Institutes of Health |
| locations[2].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | Text |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Diabetes Care |
| locations[2].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/7411279 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5089743573 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Ali Muhammed Ali |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[0].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[0].institutions[0].id | https://openalex.org/I165951966 |
| authorships[0].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Ali Muhammed Ali |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[1].author.id | https://openalex.org/A5033489906 |
| authorships[1].author.orcid | |
| authorships[1].author.display_name | Robert Martinez |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[1].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[1].institutions[0].id | https://openalex.org/I165951966 |
| authorships[1].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Robert Martinez |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[2].author.id | https://openalex.org/A5085550764 |
| authorships[2].author.orcid | |
| authorships[2].author.display_name | Hussein Al-Jobori |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[2].institutions[0].id | https://openalex.org/I165951966 |
| authorships[2].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Hussein Al-Jobori |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[3].author.id | https://openalex.org/A5086908914 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6794-6904 |
| authorships[3].author.display_name | John M. Adams |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[3].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[3].institutions[0].id | https://openalex.org/I165951966 |
| authorships[3].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | John Adams |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[4].author.id | https://openalex.org/A5083775716 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-7775-7816 |
| authorships[4].author.display_name | Curtis Triplitt |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[4].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[4].institutions[0].id | https://openalex.org/I165951966 |
| authorships[4].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Curtis Triplitt |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[5].author.id | https://openalex.org/A5073917506 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-8581-6273 |
| authorships[5].author.display_name | Ralph A. DeFronzo |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[5].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[5].institutions[0].id | https://openalex.org/I165951966 |
| authorships[5].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[5].institutions[0].type | education |
| authorships[5].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Ralph DeFronzo |
| authorships[5].is_corresponding | True |
| authorships[5].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[6].author.id | https://openalex.org/A5079024626 |
| authorships[6].author.orcid | https://orcid.org/0000-0002-2573-0208 |
| authorships[6].author.display_name | Eugênio Cersósimo |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[6].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[6].institutions[0].id | https://openalex.org/I165951966 |
| authorships[6].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[6].institutions[0].type | education |
| authorships[6].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Eugenio Cersosimo |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[7].author.id | https://openalex.org/A5111625414 |
| authorships[7].author.orcid | |
| authorships[7].author.display_name | Muhammad Abdul-Ghani |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I165951966 |
| authorships[7].affiliations[0].raw_affiliation_string | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| authorships[7].institutions[0].id | https://openalex.org/I165951966 |
| authorships[7].institutions[0].ror | https://ror.org/02f6dcw23 |
| authorships[7].institutions[0].type | education |
| authorships[7].institutions[0].lineage | https://openalex.org/I165951966 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | The University of Texas Health Science Center at San Antonio |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Muhammad Abdul-Ghani |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Division of Diabetes, University of Texas Health Science Center at San Antonio, San Antonio, TX |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdf |
| open_access.oa_status | bronze |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Combination Therapy With Canagliflozin Plus Liraglutide Exerts Additive Effect on Weight Loss, but Not on HbA1c, in Patients With Type 2 Diabetes |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10401 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 1.0 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2712 |
| primary_topic.subfield.display_name | Endocrinology, Diabetes and Metabolism |
| primary_topic.display_name | Diabetes Treatment and Management |
| related_works | https://openalex.org/W3110568386, https://openalex.org/W3013979982, https://openalex.org/W4200099789, https://openalex.org/W2370701043, https://openalex.org/W3030120986, https://openalex.org/W2334271056, https://openalex.org/W2109274758, https://openalex.org/W4300433033, https://openalex.org/W2080010254, https://openalex.org/W2405267214 |
| cited_by_count | 43 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 6 |
| counts_by_year[1].year | 2024 |
| counts_by_year[1].cited_by_count | 5 |
| counts_by_year[2].year | 2023 |
| counts_by_year[2].cited_by_count | 12 |
| counts_by_year[3].year | 2022 |
| counts_by_year[3].cited_by_count | 5 |
| counts_by_year[4].year | 2021 |
| counts_by_year[4].cited_by_count | 6 |
| counts_by_year[5].year | 2020 |
| counts_by_year[5].cited_by_count | 8 |
| locations_count | 3 |
| best_oa_location.id | doi:10.2337/dc18-2460 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S49878492 |
| best_oa_location.source.issn | 0149-5992, 1935-5548 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | False |
| best_oa_location.source.issn_l | 0149-5992 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Diabetes Care |
| best_oa_location.source.host_organization | https://openalex.org/P4310320274 |
| best_oa_location.source.host_organization_name | American Diabetes Association |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320274 |
| best_oa_location.source.host_organization_lineage_names | American Diabetes Association |
| best_oa_location.license | |
| best_oa_location.pdf_url | https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Diabetes Care |
| best_oa_location.landing_page_url | https://doi.org/10.2337/dc18-2460 |
| primary_location.id | doi:10.2337/dc18-2460 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S49878492 |
| primary_location.source.issn | 0149-5992, 1935-5548 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | False |
| primary_location.source.issn_l | 0149-5992 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Diabetes Care |
| primary_location.source.host_organization | https://openalex.org/P4310320274 |
| primary_location.source.host_organization_name | American Diabetes Association |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320274 |
| primary_location.source.host_organization_lineage_names | American Diabetes Association |
| primary_location.license | |
| primary_location.pdf_url | https://care.diabetesjournals.org/content/diacare/43/6/1234.full.pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Diabetes Care |
| primary_location.landing_page_url | https://doi.org/10.2337/dc18-2460 |
| publication_date | 2020-03-27 |
| publication_year | 2020 |
| referenced_works | https://openalex.org/W2560643142, https://openalex.org/W2189469504, https://openalex.org/W2166613497, https://openalex.org/W2157405334, https://openalex.org/W1969550954, https://openalex.org/W1986673931, https://openalex.org/W2032322539, https://openalex.org/W2106036385, https://openalex.org/W2794825506, https://openalex.org/W2519803668, https://openalex.org/W2007293458, https://openalex.org/W2887221104, https://openalex.org/W2473991910, https://openalex.org/W2600890226, https://openalex.org/W2495972436, https://openalex.org/W2793977159, https://openalex.org/W2808987855, https://openalex.org/W1943654307, https://openalex.org/W2602313931, https://openalex.org/W2514508198, https://openalex.org/W2595578651 |
| referenced_works_count | 21 |
| abstract_inverted_index.2 | 37 |
| abstract_inverted_index.= | 110, 116, 123, 159 |
| abstract_inverted_index.a | 48, 165, 180 |
| abstract_inverted_index.(P | 109, 115, 122, 143, 150, 158, 173, 183, 206 |
| abstract_inverted_index.1) | 63 |
| abstract_inverted_index.16 | 84, 87, 101 |
| abstract_inverted_index.2) | 68 |
| abstract_inverted_index.3) | 74 |
| abstract_inverted_index.9% | 166 |
| abstract_inverted_index.At | 86 |
| abstract_inverted_index.In | 199 |
| abstract_inverted_index.To | 1 |
| abstract_inverted_index.at | 217 |
| abstract_inverted_index.by | 179, 204, 243, 261, 274 |
| abstract_inverted_index.in | 103, 125, 135, 168, 186, 223, 240, 249, 256, 271 |
| abstract_inverted_index.kg | 142, 149, 157 |
| abstract_inverted_index.mg | 77, 81 |
| abstract_inverted_index.of | 5, 51, 171, 265, 279, 282 |
| abstract_inverted_index.on | 12, 41, 286 |
| abstract_inverted_index.or | 44, 73 |
| abstract_inverted_index.to | 61, 100, 236, 267 |
| abstract_inverted_index.± | 107, 113, 120, 140, 147, 155 |
| abstract_inverted_index.0.5 | 148 |
| abstract_inverted_index.0.8 | 141, 156 |
| abstract_inverted_index.1.2 | 65, 76 |
| abstract_inverted_index.100 | 70, 80 |
| abstract_inverted_index.15% | 205 |
| abstract_inverted_index.50% | 181 |
| abstract_inverted_index.9-h | 49 |
| abstract_inverted_index.AND | 27 |
| abstract_inverted_index.EGP | 52, 90, 172, 202, 241, 272 |
| abstract_inverted_index.The | 95, 133, 263 |
| abstract_inverted_index.and | 18, 118, 130, 153, 196, 219, 252 |
| abstract_inverted_index.for | 83 |
| abstract_inverted_index.the | 3, 89, 211, 220, 238, 247, 254, 269, 277 |
| abstract_inverted_index.two | 284 |
| abstract_inverted_index.was | 92, 105, 138, 177, 215, 227 |
| abstract_inverted_index.CANA | 162 |
| abstract_inverted_index.EGP. | 198 |
| abstract_inverted_index.LIRA | 190 |
| abstract_inverted_index.body | 19, 136 |
| abstract_inverted_index.each | 22 |
| abstract_inverted_index.even | 209 |
| abstract_inverted_index.from | 98 |
| abstract_inverted_index.lack | 278 |
| abstract_inverted_index.mean | 96 |
| abstract_inverted_index.plus | 10, 78 |
| abstract_inverted_index.rate | 170 |
| abstract_inverted_index.rise | 222, 248 |
| abstract_inverted_index.that | 233 |
| abstract_inverted_index.they | 58 |
| abstract_inverted_index.type | 36 |
| abstract_inverted_index.were | 59 |
| abstract_inverted_index.with | 8, 31, 43, 53 |
| abstract_inverted_index.0.05) | 185 |
| abstract_inverted_index.0.24% | 114 |
| abstract_inverted_index.0.29% | 108 |
| abstract_inverted_index.0.39% | 121 |
| abstract_inverted_index.CANA, | 129 |
| abstract_inverted_index.HbA1c | 104 |
| abstract_inverted_index.LIRA, | 131 |
| abstract_inverted_index.These | 230 |
| abstract_inverted_index.after | 56 |
| abstract_inverted_index.basal | 169 |
| abstract_inverted_index.block | 237 |
| abstract_inverted_index.these | 283 |
| abstract_inverted_index.weeks | 102 |
| abstract_inverted_index.which | 57, 176 |
| abstract_inverted_index.(EGP), | 17 |
| abstract_inverted_index.(HbA1c | 34 |
| abstract_inverted_index.(T2DM) | 40 |
| abstract_inverted_index.0.004) | 124 |
| abstract_inverted_index.0.03), | 160 |
| abstract_inverted_index.0.05), | 175, 208 |
| abstract_inverted_index.DESIGN | 26 |
| abstract_inverted_index.HbA1c, | 13 |
| abstract_inverted_index.HbA1c. | 287 |
| abstract_inverted_index.agents | 285 |
| abstract_inverted_index.alone. | 24 |
| abstract_inverted_index.caused | 164, 242, 260, 273 |
| abstract_inverted_index.effect | 4, 281 |
| abstract_inverted_index.failed | 235 |
| abstract_inverted_index.mg/day | 66, 71 |
| abstract_inverted_index.plasma | 187, 193, 212, 224, 250, 257 |
| abstract_inverted_index.poorly | 32 |
| abstract_inverted_index.ratio. | 189 |
| abstract_inverted_index.though | 210 |
| abstract_inverted_index.versus | 21 |
| abstract_inverted_index.weeks, | 88 |
| abstract_inverted_index.weeks. | 85 |
| abstract_inverted_index.weight | 20, 137 |
| abstract_inverted_index.−1.9 | 154 |
| abstract_inverted_index.−3.5 | 146 |
| abstract_inverted_index.−6.0 | 139 |
| abstract_inverted_index.(CANA), | 72 |
| abstract_inverted_index.(LIRA), | 67 |
| abstract_inverted_index.0.002), | 117 |
| abstract_inverted_index.METHODS | 28 |
| abstract_inverted_index.RESULTS | 94 |
| abstract_inverted_index.despite | 245 |
| abstract_inverted_index.examine | 2 |
| abstract_inverted_index.failure | 264 |
| abstract_inverted_index.glucose | 15 |
| abstract_inverted_index.insulin | 213, 258 |
| abstract_inverted_index.prevent | 268 |
| abstract_inverted_index.receive | 62 |
| abstract_inverted_index.reduced | 192 |
| abstract_inverted_index.results | 231 |
| abstract_inverted_index.therapy | 7, 23 |
| abstract_inverted_index.without | 45 |
| abstract_inverted_index.−0.89 | 112 |
| abstract_inverted_index.−1.44 | 119 |
| abstract_inverted_index.−1.67 | 106 |
| abstract_inverted_index.&lt; | 144, 151, 174, 184, 207 |
| abstract_inverted_index.0.0001), | 111, 145, 152 |
| abstract_inverted_index.7–11%) | 35 |
| abstract_inverted_index.RESEARCH | 25 |
| abstract_inverted_index.additive | 280 |
| abstract_inverted_index.baseline | 99, 218 |
| abstract_inverted_index.blocked. | 228 |
| abstract_inverted_index.blocking | 246 |
| abstract_inverted_index.decrease | 97, 134, 255 |
| abstract_inverted_index.diabetes | 38 |
| abstract_inverted_index.explains | 276 |
| abstract_inverted_index.glucagon | 194, 225, 251 |
| abstract_inverted_index.increase | 167, 182, 239, 270 |
| abstract_inverted_index.mellitus | 39 |
| abstract_inverted_index.patients | 30, 126 |
| abstract_inverted_index.received | 47 |
| abstract_inverted_index.response | 214 |
| abstract_inverted_index.OBJECTIVE | 0 |
| abstract_inverted_index.increased | 203 |
| abstract_inverted_index.infusion, | 55 |
| abstract_inverted_index.inhibited | 197 |
| abstract_inverted_index.metformin | 42 |
| abstract_inverted_index.patients, | 201 |
| abstract_inverted_index.receiving | 127 |
| abstract_inverted_index.repeated. | 93 |
| abstract_inverted_index.CANA/LIRA, | 128 |
| abstract_inverted_index.Forty-five | 29 |
| abstract_inverted_index.controlled | 33 |
| abstract_inverted_index.endogenous | 14 |
| abstract_inverted_index.maintained | 216 |
| abstract_inverted_index.preventing | 253 |
| abstract_inverted_index.production | 16 |
| abstract_inverted_index.randomized | 60 |
| abstract_inverted_index.(CANA/LIRA) | 82 |
| abstract_inverted_index.CONCLUSIONS | 229 |
| abstract_inverted_index.accompanied | 178 |
| abstract_inverted_index.combination | 6 |
| abstract_inverted_index.demonstrate | 232 |
| abstract_inverted_index.liraglutide | 11, 64, 75, 234, 266 |
| abstract_inverted_index.measurement | 50, 91 |
| abstract_inverted_index.monotherapy | 163, 191 |
| abstract_inverted_index.CANA-induced | 221 |
| abstract_inverted_index.sulfonylurea | 46 |
| abstract_inverted_index.[3-3H]glucose | 54 |
| abstract_inverted_index.canagliflozin | 9, 69, 79, 244, 275 |
| abstract_inverted_index.concentration | 195, 226, 259 |
| abstract_inverted_index.respectively. | 132, 161 |
| abstract_inverted_index.canagliflozin. | 262 |
| abstract_inverted_index.CANA/LIRA-treated | 200 |
| abstract_inverted_index.glucagon-to-insulin | 188 |
| cited_by_percentile_year.max | 99 |
| cited_by_percentile_year.min | 97 |
| corresponding_author_ids | https://openalex.org/A5073917506 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 8 |
| corresponding_institution_ids | https://openalex.org/I165951966 |
| citation_normalized_percentile.value | 0.95703426 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |